Cingulate Stock (NASDAQ:CING)


OwnershipFinancialsChart

Previous Close

$4.81

52W Range

$1.80 - $156.00

50D Avg

$6.00

200D Avg

$16.67

Market Cap

$14.83M

Avg Vol (3M)

$3.88M

Beta

-0.93

Div Yield

-

CING Company Profile


Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Dec 08, 2021

Website

CING Performance


CING Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-22.76M$-17.50M$-20.68M
Net Income$-23.54M$-17.85M$-20.74M
EBITDA$-22.76M$-17.50M$-19.97M
Basic EPS-$-31.57$-36.68
Diluted EPS-$-31.57$-36.68

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
SNTISenti Biosciences, Inc.
BLCMBellicum Pharmaceuticals, Inc.
PMVPPMV Pharmaceuticals, Inc.
DYAIDyadic International, Inc.
MNPRMonopar Therapeutics Inc.
IKTInhibikase Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
HILSTharimmune, Inc.
ANTXAN2 Therapeutics, Inc.
RZLTRezolute, Inc.
GNLXGenelux Corporation
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.